All News

At the end of April, FDA approved a new biologic to help prevent and control bleeding in patients with hemophilia B who are 12 years and older. It also is approved for use in perioperative management in this patient population.

The National Association of Boards of Pharmacy (NABP) recently issued a report listing illegal online drug sellers and detailing the threat they pose to the public.

An investigational vaccine for herpes zoster provided significant benefit to patients 50 and older, with little difference in efficacy among those in their 50s, 60s, and 70s, according to a phase 3 international trial [Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50)].

Cornell Prescription Pharmacy has agreed to pay the federal government $125,000 to settle charges it improperly disposed of the patient information of more than 1,600 people in an unlocked, open container in 2012.

About 6,000 healthcare workers, including pharmacists, will be enrolled in a new clinical trial in Sierra Leone to test the safety and efficacy of the rVSV-ZEBOV candidate Ebola vaccine, the Centers of Disease Control and Prevention (CDC) recently announced.

Eleven of the most promising biosimilars will create an estimated $250 billion in savings for U.S. payers, according to pharmacy benefits manager Express Scripts.

Four generic manufacturers (Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals, and Torrent Pharmaceuticals) received the go-ahead April 28 to market their generic versions for Abilify for the treatment of schizophrenia and bipolar disorder.

FDA approved Sandoz’s generic version of Copaxone (glatiramer acetate injection) known as Glatopa, making it the first generic version of the drug available for patients with relapsing forms of multiple sclerosis.

The Office of Inspector General of the U.S. Department of Health & Human Services (HHS) recently announced it would investigate price increases for generic drugs in the Medicaid drug rebate program.

The pharmaceutical and healthcare industry is lauding the FDA’s approval of the first biosimilar product this year, noting that the drugs could save the U.S. healthcare system billions of dollars.

Last year, more women than men were practicing pharmacy or working in pharmacy-related careers. And there were more women managers than ever before.

Pharmacists swear an oath to do no harm. But what about patients? Should they be responsible for their behavior toward us?